Uploaded August 2025 | Updated September 2026, 2 weeks ago
This month, the Department of Health and Human Services terminated almost $500 million in mRNA vaccine development grants and contracts. While HHS has said that these cuts won't affect mRNA cancer research, some researchers have expressed concern about the impact on their ongoing work. In light of these developments, we’re revisiting a conversation from February.
A team at Memorial Sloan Kettering is developing an mRNA vaccine for pancreatic cancer, which is notoriously difficult to treat. A few years ago, the team embarked on a small trial to test the vaccine’s safety. Sixteen patients with pancreatic cancer received it, and half of them had a strong immune response. A follow-up study found that in six of those patients, the cancer hadn’t relapsed after three years.
Host Flora Lichtman spoke to study author Vinod Balachandran about the work, which has not yet been affected by the cuts, according to Memorial Sloan Kettering.
Guest:
Dr. Vinod Balachandran is an associate attending surgeon and Director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering in New York, New York.
Subscribe to our podcast and never miss your daily dose of science: pod.link/73329284
This month, the Department of Health and Human Services terminated almost $500 million in mRNA vaccine development grants and contracts. While HHS has said that these cuts won't affect mRNA cancer research, some researchers have expressed concern about the impact on their ongoing work. In light of these developments, we’re revisiting a conversation from February.
A team at Memorial Sloan Kettering is developing an mRNA vaccine for pancreatic cancer, which is notoriously difficult to treat. A few years ago, the team embarked on a small trial to test the vaccine’s safety. Sixteen patients with pancreatic cancer received it, and half of them had a strong immune response. A follow-up study found that in six of those patients, the cancer hadn’t relapsed after three years.
Host Flora Lichtman spoke to study author Vinod Balachandran about the work, which has not yet been affected by the cuts, according to Memorial Sloan Kettering.
Guest:
Dr. Vinod Balachandran is an associate attending surgeon and Director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering in New York, New York.
Subscribe to our podcast and never miss your daily dose of science: pod.link/73329284
